a publicly-held biotechnology company that is a spin off of the musculoskeletal transplant foundation (mtf) using technology discovered and licensed from ucla. bone biologics market and focus is in the regenerative medicine orthobiologics space. bone biologics was founded in 2004 by university of california professors in collaboration with an osaka university professor and a usc surgeon and acquired in 2006 by mtf as the major shareholder, who has been the primary funder since the acquisition. the company’s proprietary, patented platform technology ucb-1™, exclusively licensed from ucla, has met and surpassed existing standards of care outcomes in completed large animal model (sheep and rhesus monkey) studies that have demonstrated that the ucb-1™ technology facilitates superior normal bone growth. the company believes that as a platform technology, ucb-1™ has broad applications in delivering improved outcomes in almost all surgical procedures involved in bone repair and regeneration.
Company profile
Ticker
BBLG
Exchange
Website
CEO
Jeffrey Frelick
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
Former names
AFH ACQUISITION X, INC., Bone Biologics, Corp.
SEC CIK
BBLG stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
15 Mar 24
8-K
Bone Biologics Announces Pricing of $2.0 Million Public Offering
6 Mar 24
EFFECT
Notice of effectiveness
5 Mar 24
424B4
Prospectus supplement with pricing info
4 Mar 24
8-K
Bone Biologics Reports Progress with NB1 Clinical Program
1 Mar 24
S-1/A
IPO registration (amended)
26 Feb 24
S-1/A
IPO registration (amended)
23 Feb 24
10-K
2023 FY
Annual report
21 Feb 24
S-1
IPO registration
30 Jan 24
EFFECT
Notice of effectiveness
25 Jan 24
Latest ownership filings
SC 13G
INTRACOASTAL CAPITAL, LLC
14 Mar 24
SC 13G/A
Ionic Ventures, LLC
14 Feb 24
SC 13G/A
Walleye Capital LLC
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
4
Deina H Walsh
19 Jan 24
4
Jeff Frelick
19 Jan 24
4
Robert E. Gagnon
10 Jan 24
3
Robert E. Gagnon
10 Jan 24
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
SC 13G/A
Ionic Ventures, LLC
20 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 2 |
Closed positions | 8 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 1.10 mm |
Total shares | 2.96 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Hankey Don | 2.47 mm | $562.00 k |
Intracoastal Capital | 224.45 k | $175.00 k |
Lind Global Fund II | 203.05 k | $319.00 k |
IOI Ionic Ventures | 55.19 k | $43.00 k |
Sabby Management | 9.88 k | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Jan 24 | Jeff Frelick | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.61 | 25,000 | 90.25 k | 25,000 |
17 Jan 24 | Deina H Walsh | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.61 | 12,500 | 45.13 k | 12,500 |
8 Jan 24 | Gagnon Robert E. | Non-Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.68 | 8.006 | 37.47 | 8,015 |
8 Jan 24 | Gagnon Robert E. | Non-Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.68 | 9 | 42.12 | 9 |
18 Sep 23 | Erick Lucera | Non-Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.64 | 85,763 | 54.89 k | 85,763 |
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
20 Mar 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
4 Mar 24
12 Health Care Stocks Moving In Friday's After-Market Session
1 Mar 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
1 Mar 24
Bone Biologics Reports Progress With NB1 Clinical Program
1 Mar 24
Press releases
Bone Biologics Announces Closing of $2.0 Million Public Offering
6 Mar 24
Bone Biologics Announces Pricing of $2.0 Million Public Offering
4 Mar 24
Bone Biologics Reports Progress With NB1 Clinical Program
1 Mar 24
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
11 Jan 24
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
10 Jan 24